I2MC

THE INSTITUTE…

The Institute of Metabolic and Cardiovascular Diseases (I2MC) develops research to understand the pathophysiological mechanisms involved in common chronic non-communicable diseases: obesity, diabetes, thrombosis, atherosclerosis and diseases of the vessels, heart and kidney.

HISTORY

The Institute of Metabolic and Cardiovascular Diseases (I2MC) was created in 2011 from the merger of pre-existing research units located near the clinical services of the Toulouse Rangueil University Hospital. The I2MC has been renewed in 2021 for a 6-year term by Inserm and the University Toulouse III – Paul Sabatier (UMR 1297). The I2MC is composed of 11 research teams and 7 technological platforms for a total staff of 280 people. Scientists and clinicians work on metabolic risk factors (obesity, diabetes and dyslipidemia) and their cardiovascular complications (vascular diseases, thrombosis, atherosclerosis, heart and kidney failure). The I2MC has recognized expertise in cell biology, mouse models and clinical work supported by skills in lipidomics, genomics, proteomics, animal phenotyping and cellular imaging. The I2MC is at the center of a very active network of local, national and international collaborations. The I2MC offers opportunities to work on major chronic diseases in human health in the highly appreciated environment of Toulouse.
 

Scientists

Teams

 

 

 

2 RESEARCH

AXES

 

publications per year

technological platforms

Parent institutions and partners

Main financial supporters

management team

Trained as a veterinarian, Dominique Langin obtained a Master’s degree and a PhD in France before doing a post-doctoral fellowship at the University of Lund in Sweden and embarking on a scientific career at the CNRS and Inserm. He is currently a University Professor – Hospital Practitioner at the University Hospital of Toulouse and at the University Toulouse III – Paul Sabatier. His research combines cellular, animal and human studies. He has participated in national and European research projects and obtained a Synergy grant from the European Research Council in 2020. He has dedicated his scientific career to the study of the biology of adipose tissue, obesity and diabetes with a particular focus on fatty acid metabolism. He has received several awards including the Friedrich Wassermann Life Time Achievement Award from the European Association for the Study of Obesity in 2011 and the Labbé Prize from the French Academy of Sciences in 2019. In 2021, he was named a member of the “Institut Universitaire de France“.
 
 
Dominique LANGIN

Director of the Institute of Metabolic and Cardiovascular Diseases (I2MC)

Pierre GOURDY

Deputy Director

Karine MOREIRA

Administrative Director

Frank LEZOUALC'H

Project Manager

Joost SCHANSTRA

Project Manager

Alexia ZAKAROFF

Project Manager

L’organisation de l’I2MC

Research teams

Technological platforms

Administration and support services

Laboratory Council

Scientific advisory board

An independent Strategic Scientific Committee (SAB), composed of experts in the Institute’s scientific fields, both French and foreign, is appointed by the Director of the I2MC. Its objective is to examine the Institute’s strategies, its organization and that of its teams in order to prepare and optimize each evaluation by the national supervisory authorities. The SAB advises the director and the team leaders in order to improve the organization of the Institute and its scientific production.
 
 

Actualités

DISEASES explained

Type 2 diabetes

Diabetes is a long-term excess of glucose concentration in the blood (hyperglycemia). In the case of type 2 diabetes, this is caused by a disturbance of the carbohydrate metabolism. Even if it appears gradually and insidiously, the disease has serious consequences, even fatal, in the long term.

 

Cardiovascular diseases

Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. CVDs are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions.

Kidney disease

Kidney failure is the result of the slow evolution of the disease that leads to the destruction of the kidneys. It affects more than 82,000 people in France and requires dialysis or transplantation. In 50% of cases, chronic kidney diseases are the consequence of diabetes or high blood pressure.

Obesity

Obesity is an excess of body fat and a change in adipose tissue, which can lead to health problems and shorten life expectancy. Its causes are complex. It results from the interplay of several factors – dietary, genetic, epigenetic and environmental – involved in the development and progression of this chronic disease.

 

Non-profit and patient associations

L’Afero

A.F.E.R.O is the French Association for Study and Research on Obesity. Its aim is to promote scientific exchanges, the dissemination of knowledge and training in the field of biomedical research on obesity. The AFERO can be considered as the learned society of Obesity in France.

 

French-speaking Society of Nephrology, Dialysis and Transplantation

The mission of the SFNDT is to support the development of nephrology in all its fields, from clinical nephrology to dialysis and renal transplantation, as well as in all dimensions of care, basic research, epidemiological and clinical advances, and education.

 

French Federation of Cardiology

Created in 1964, the French Federation of Cardiology is an association recognized as being of public utility since 1977. A collective vocation mobilized to reduce cardiovascular diseases.

 

Évènements

George CAPUTA videoconference on the 7th of october at 11h : Nature ‘s editorial policy

On the 7th of October at 11h00, George CAPUTA(*) will speak by videoconference to present Nature’s editorial policy, in particular in the field of metabolic and cardiovascular diseases, and to answer your questions.

The 1st Simple Western users’ Day

The We-Met platform and the I2MC are hosting the 1st Simple Western French Users’ Day on 11 and 12 October. Free, but mandatory, registration for all Simple Western users.

New method for global plasma lipid profiling by SFC-MS

The MetaToul-Lipidomics platform has developed a method for profiling plasma lipids by supercritical fluid chromatography (SFC) coupled with mass spectrometry.

Acquisition of a Cytek AURORA CS Spectral Analyser/Sorter

Thanks to a European REACT-EU grant, the I2MC’s Genotoul Cytometry -TRI platform will be equipped with a new Aurora CS Cytek spectral cell analyser/sorter by the end of December 2021. 

Congratulations to the new recruits!

I2MC is delighted to welcome 3 researchers and assistant professor :
Marine ADLANMERINI (CRCN Team F. Lenfant/P. Gourdy), Claire LAURENS (MCU Team C. Moro/D. Langin), Natalia SMIRNOVA (CRCN Team M. Laffargue)

2nd Symposium on Aging in Occitanie

The INSPIRE network in Toulouse and the M.A.N. network in Montpellier are organizing a symposium on 17 September, 9.30 a.m., bringing together academic actors working on the theme of Ageing, at the I2MC.
@: montpellier.aging.network@gmail.com

Derniers tweets

logotype i2mc
logotype i2mc

Inserm/UPS UMR 1297 - I2MC Institut des Maladies Métaboliques et Cardiovasculaires

1 avenue Jean Poulhès - BP 84225 - 31432 Toulouse Cedex 4

Tél. : 05 61 32 56 00

Contactez-nous

 

Horaires

Du lundi au vendredi
8h30 - 12h30 / 13h45 -16h45